ArticleBMC cancer2016
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2022Pooled it
- Serial CSF CA19-9 monitoring and CSF genomic profiling in ERBB2-mutant lung adenocarcinoma with leptomeningeal metastasis: a case report.Frontiers in oncology · 2026Article
- Risk factors and predictive model of lymph node metastasis in clinical stage IA peripheral non-small cell lung cancer: a retrospective study.BMC cancer · 2025Article
- Paraneoplastic Effects of Lung Adenocarcinoma Causing Persistently Elevated Lipase, Amylase, and CA 19-9.ACG case reports journal · 2025Article
- Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025Review
- Lung Adenocarcinoma Presenting With Elevated Serum Carbohydrate Antigen 19-9 Levels: A Case Report.Cureus · 2025Article
- Combined inflammatory-lipid index and tumor markers for predicting the spatial localization of lesions in early-stage non-small cell lung cancer.Frontiers in oncology · 2025Article
- Quantitative site-specific N-glycosylation analysis reveals IgG glyco-signatures for pancreatic cancer diagnosis.Clinical proteomics · 2024Article
- Mass spectrometry analysis of intact proteinJournal of Zhejiang University. Science. B · 2024Article
- Exploring the Role of Biomarkers Associated with Alveolar Damage and Dysfunction in Idiopathic Pulmonary Fibrosis-A Systematic Review.Journal of personalized medicine · 2023Review
- Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.International journal of molecular sciences · 2022Review
- Diagnosis and treatment of primary pulmonary enteric adenocarcinoma: Report of Six cases.World journal of clinical cases · 2021Article
- Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease.Scientific reports · 2021Article
- Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.World journal of gastrointestinal surgery · 2020Review
- Primary hepatoid adenocarcinoma of lung: A rare malignancy mimicking tuberculosis.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to assess the prognostic accuracy of serum CA 19-9 in patients with advanced lung adenocarcinoma.
methodsWe retrospectively reviewed data of 246 patients who were diagnosed at our institute with advanced (stage IIIB or IV) lung adenocarcinoma between March 2006 and December 2012. We excluded patients who received no chemotherapy, or for whom we had no data on pre-treatment tumor markers. We also evaluated 116 consecutive resected specimens from patients with clinical stage I lung adenocarcinoma pathologically.
resultsThe 76 (31 %) patients who were CA 19-9
conclusionsCA 19-9 and CYFRA 21-1 are independent prognostic markers in patients with advanced lung adenocarcinoma. Combined use of CA 19-9 and CYFRA 21-1 provides further prognostic information in patients with advanced lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.